In this article, we will look at the 5 Stocks to Watch Right Now. For a deeper discussion and an extended list, please see 10 Stocks to Watch Right Now: Equinor, JD, Marvell, and More.

5. Amprius Technologies Inc. (NYSE:AMPX)

Amprius rallied for a fifth straight day on Friday to hit a new all-time high, as investor optimism was further bolstered by two analysts’ price target upgrades and bullish ratings for its stock.

At intra-day trading, the stock soared to its highest price of $17.29 before paring gains to finish the day just up by 9.67 percent at $16.33 apiece.

In separate market reports, Cantor Fitzgerald and Craig-Hallum raised their price targets for Amprius Technologies Inc. (NYSE:AMPX) to $20 and $21, from $16 and $17, respectively.

Cantor issued an “overweight” rating while Craig-Hallum assigned a “buy” recommendation, following Amprius Technologies Inc.’s (NYSE:AMPX) highly optimistic outlook this year, with revenues targeted to grow by 71 percent.

In its latest earnings call, Amprius Technologies Inc. (NYSE:AMPX) said that it is targeting to further grow its revenues to $125 million this year from $73 million last year. If realized, the company would end the year with a 417-percent revenue jump in just two years, versus only $24.17 million in 2024.

However, it expects to remain at a net loss of $8 million in 2026, but would imply an 82-percent recovery from $44 million in net losses last year.

“2025 marked a year of meaningful commercial progress, as we expanded our customer base to over 550, increased revenue by over 3x, and advanced the adoption of our silicon anode batteries across multiple end markets,” Amprius Technologies Inc. (NYSE:AMPX) CEO Tom Stepien said.

“Growing demand from existing customers, new program wins, and improved execution across our manufacturing partners drove strong momentum throughout the year. Looking ahead to 2026, we plan to leverage our enhanced supply chain to scale production and meet accelerating market demand, supporting continued accretive growth,” he added.

4. Iovance Biotherapeutics Inc. (NASDAQ:IOVA)

Iovance climbed to a new 52-week high on Friday, extending a three-day run, as investors gobbled up shares after an investment firm doubled its price target for its stock.

At intra-day trading, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) climbed to its highest price of $5.34 before paring gains to finish the session just up by 12.01 percent at $5.13 apiece.

In a market report, UBS raised its price target for the biopharmaceutical company to $4 from $2 previously, albeit remaining “neutral” for the stock.

On the other hand, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) maintained a more bullish rating from Wells Fargo, with the investment firm reaffirming its $14 price target and “buy” recommendation.

On Wednesday, March 11, investors will be closely watching out for business updates from Iovance Biotherapeutics Inc. (NASDAQ:IOVA) amid its participation in Barclays’ 28th Annual Global Healthcare Conference.

In recent news, the biopharmaceutical firm reported a 5 percent wider net loss last year at $390.98 million versus $372 million in 2024. Total revenues jumped by 60.6 percent to $263.5 million from $164.07 million year-on-year.

In the fourth quarter alone, net loss narrowed by 8 percent to $71.9 million from the $78.5 million in the same period a year earlier, while revenues increased by 17.6 percent to $86.7 million from $73.69 million year-on-year.

3. Marvell Technology Inc. (NASDAQ:MRVL)

Marvell Technology soared by 18.35 percent on Friday to close at $89.57 apiece, as investors took heart from its strong earnings performance for the full fiscal year 2026, swinging to billions of profits from hundred millions of net losses a year earlier.

In an updated report, Marvell Technology Inc. (NASDAQ:MRVL) said that it incurred a $2.67 billion net income in the full fiscal year ending January 31, reversing an $885 million net loss in fiscal 2025.

Net revenues jumped by 42 percent to $8.2 billion from $5.77 billion year-on-year.

In the fourth quarter alone, net income stood at $396.1 million, nearly double the $200.2 million in the same period a year earlier. Net revenues increased by 22 percent to $2.2 billion from $1.8 billion year-on-year.

Marvell Technology Inc. (NASDAQ:MRVL) Chairman and CEO Matt Murphy attributed the company’s strong performance from the robust AI demand.

Looking ahead, the company is targeting net revenues for the first quarter of fiscal year 2027 at a midpoint of $2.4 billion, or a 27 percent jump from the $1.895 billion reported in the same period a year earlier.

GAAP diluted earnings per share are targeted at $0.31, plus or minus $0.05, versus $0.20 year-on-year.

2. Samsara Inc. (NYSE:IOT)

Samsara soared by 19.54 percent on Friday to finish at $35.36 apiece, as investor sentiment was bolstered by a stellar earnings performance, having nearly wiped out its losses in the last fiscal year.

In an updated report, Samsara Inc. (NYSE:IOT) said that it narrowed its net losses by 94 percent to $9 million in the fiscal year ending January 31, from a $155 million net loss a year earlier.

Revenues also jumped by 28 percent to $1.6 billion from $1.25 billion year-on-year.

In the fourth quarter alone, Samsara Inc. (NYSE:IOT) swung to a net income of $22 million, reversing a net loss of $11.2 million in the same quarter a year earlier. Revenues increased by 28 percent to $444.3 million from $346 million year-on-year.

“Fiscal year 2026 was an outstanding year of durable and efficient growth,” Samsara Inc. (NYSE:IOT) CEO Sanjit Biswas said, adding that the performance was driven by the scale of its data asset, which now captures more than 25 trillion data points annually to fuel its AI-powered platform.

For the first quarter of fiscal year 2027, the company is targeting to generate revenues of $454 million to $456 million, or an implied growth of 24 percent year-on-year.

For the full fiscal 2027 alone, revenues are expected to grow between 21 and 22 percent to a range of $1.965 billion to $1.975 billion year-on-year.

1. Day One Biopharmaceuticals Inc. (NASDAQ:DAWN)

Day One soared to a new three-year high on Friday, as investors gobbled up shares following news that it is set to merge with France-based Servier for $2.5 billion.

In a joint statement, Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) and Servier said that they have entered into a definitive agreement under which the latter would acquire the former’s shares at a price of $21.50 apiece. The figure marked a 68 percent upside from its latest closing price.

Following the news, shares of Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) at intra-day trade soared to its highest price of $21.23 before paring a few cents to finish the session just up by 65.88 percent at $21.20 apiece.

According to the companies, they expect to close the transaction in the second quarter of the year, subject to customary closing conditions

“Servier’s successful track record in rare cancers and its commitment to advancing targeted therapies make it the ideal home for our portfolio as part of Day One’s mission to bring medicines to patients of all ages with life-threatening diseases,” Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) CEO Jeremy Bender said.

“Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low‑grade glioma. Importantly, Servier’s dedication to the rare disease community preserves the patient‑first mindset that has defined our company since the beginning and has driven our deep commitment to the communities we serve,” he noted.

While we acknowledge the potential of DAWN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DAWN and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.